Being one of the most aggressive forms of cancer, melanoma is extremely difficult to treat. To date, there is protivomigrenosny experimental vaccine, but it does not provide dolozhny result. However, a group of researchers from the USA were able to significantly improve the cure and survival of laboratory specimens up to 100%.
For the study, responsible scientists from the research Institute of SCRIPPS. They added the vaccine to something like “amplifier” is a molecule Diprovocim. And the results of the tests prove that a new vaccine can greatly increase the chances of survival, even if drug therapy is not effective.
In laboratory tests, the vaccine was tested on laboratory mice with an aggressive form of melanoma, previously treated. Then the mice were divided into 3 groups. First received only the conventional vaccine and the second vaccine, enhanced Diprovocim. The third group was not vaccinated at all. As a result, after 54 days in group 2 was observed 100% survival of individuals in group 1 survived only 25% of rodents, and group 3 died completely. As stated by one of the authors Dale Boger,
“Our research shows that the vaccine is highly effective combined with immune therapy. This is a wonderful result. The main advantage lies in the fact that the vaccine is injected into the blood. It is not necessary to enter accurately into the tumor.”
Now scientists plan to continue a series of experiments to develop a more precise treatment regimens and evaluation of the long-term effect of a new method of therapy.
This and other news you can discuss in our telegram chat.
The melanoma vaccine has provided 100% survival during the test